



Introduction Presentation

March 2026

Disclaimer

This document and presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any forward-looking statements included in this document and presentation are subject to various risk factors that may cause actual results to differ materially from our current expectations. We have no current intention of updating the forward-looking statements contained in this document except to the extent required by law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this document.

Agenda

- SMSbiotech introduction
- Small Mobile Stem cells (SMS cells)
- SMS Cell Platform technology
- Clinical data overview
- Sample case studies & testimonial
- SMS Pricing
- Onboarding Process
- SMS cell production / clinic ordering
- SMSbiotech IP
- Next Steps




SMSbiotech Introduction

SMSbiotech is a clinical-stage company that has discovered and named a new type of stem cell called the Small Mobile Stem cell.

- Unique **non-genetically modified** SMS cells are scaled up to industrial level providing **resilient, stable cells** with **consistent quality** and storage ability at **refrigerator temperature** for at **least 3 weeks**
- Our patented, regenerative platform technology **promotes restoring and healing damaged and diseased cells and tissues**
- The **platform technology** creates multiple solutions for multiple diseases demonstrated in various animal models
- This newly discovered technology is **ethically sourced from living human adults** and are **donor-independent**
- While other stem cells exist, none have the **capabilities and the mechanisms** of Small Mobile Stem (SMS) cells
- SMS cells platform technology addresses **chronic diseases** - for the first time, off-the-shelf cell therapy and a potential cure for the currently incurable **Chronic Obstructive Pulmonary Disease (COPD)**.

Small Mobile Stem (SMS) Cells Characteristics:

Fast, Transparent, Escaped Detection




Unique Higher-Order Biological Adaptability

A New Class of Adaptive Stem Cells

- Small Mobile Stem (SMS) cells are robust, highly motile stem cells that circulate systemically and function as intelligent biological messengers.
- Unlike conventional stem cells that follow linear differentiation pathways, SMS cells uniquely sense and respond to tissue-specific microenvironments, withstand hostile conditions, and dynamically orchestrate repair through organ-tailored modulation of gene expression programs.

Key Characteristics

- Adult, non-genetically modified
- Ultra small size
- Low metabolic demand
- signal-driven repair
- Limited differential potential



Small Mobile Stem (SMS) Cells VS. Other Stem Cells

Why SMS Cells Stand Apart

- Sustained Proliferation & Scalability: Capable of long-term expansion in culture without donor limitations.
- Genomic Stability & Safety: Stable genome, low mitochondrial load, and reduced tumorigenic risk compared to ESCs and iPSCs.
- Ethically Sound: No embryonic sourcing or complex reprogramming processes.
- Maintained Potency Over Time: Preserve differentiation capacity beyond traditional adult stem cell limits.
- Resilient & Clinically Robust: Small, durable, and highly responsive to cellular induction.

	SMS Cells	MSC	iPSC	Embryonic Stem Cells	Other Competitive Modalities
Safety	✓	⚠	✗	✗	⚠
Stability	✓	✓	✗	⚠	⚠
Ethics	✓	✓	⚠	✗	⚠
Scalability	✓	⚠	⚠	⚠	⚠


SMS Cell Platform Technology: Opportunities and Verticals

SMSbiotech's therapeutic pipeline spans multiple indications. Current programs range from research and pre-clinical development to anticipated clinical submissions, with compassionate use pathways under consideration.

Indications	Compassionate Use	Research	Development	Pre-Clinical	Submission	Phase i/ii	Phase ii/iii	Registration	
Respiratory									
COPD	✓								
Lung Fibrosis									
Orthopedic									
Joint Therapy (Human)	✓								
Disc Degeneration (Human)	✓								
Joint Therapy (Veterinarian)	✓								
Disc Degeneration (Veterinarian)	✓								
Cardiovascular Diseases									
Microvascular Diseases	✓								
Other Indications									
Different indications	✓								
Cosmeceutical									
Skin Anti-Aging									
Scarring									

Clinical Use Cases

SMS cells have demonstrated safety, tolerability, and regenerative potential across preclinical models and early clinical use cases, including first-in-class inhaled delivery for COPD. Backed by zero safety incidences and a favorable clinical profile, the platform supports broad therapeutic expansion with confidence.



Preclinical Models

Clinical Applications

Outcomes & Safety

Preclinical Disease Models

- Rat – COPD (Primary Efficacy Model)
- Equine – Tendon injury
- Canine – Open wound healing
- Canine – Joint conditions

Early Clinical Applications

- Multiple routes of administration
- Respiratory (inhaled delivery)
- Orthopedic and soft tissue applications

Outcomes & Safety Profile

- Zero reported safety incidences
- Zero reported autoimmune reactions
- Favorable tolerability profile
- Supporting white papers and data available

SMS Cell Pricing

- Market priced, reviewed each 6 months
- Priced at a premium of MSC
- Sold per patient treatment (volume)
- FOB – SMSbiotech to work with clinic on regulatory compliant means of import/delivery
- Discounted pricing for clinics with research MOU in place
- Onboarding includes sampling allowance – especially for clinicians
- Kickstarter initiative offers 1st 30 treatments at \$US 1K per treatment
- SMSbiotech patient referral program



MEXICO
Clinical Program Pricing
 For authorized clinical partners only

Localized SMS Cell Therapy

Designed for targeted tissue repair across orthopedic and aesthetic applications.

Clinical Application	Treatment Structure	Program Price
Aesthetic Applications	Topical application	\$400
Orthopedic Indications*	Single-dose injection	\$2,600

*Orthopedic indications include: Achilles tendon, patellar tendon, knee, hip, shoulder, rotator cuff, elbow, wrist/hand, and carpal tunnel.

Pulmonary Regenerative Programs

SMS cell-based regenerative programs designed to support pulmonary tissue repair and functional recovery.

Program	Treatment Structure	Program Price
Lung Regeneration Program	Single-dose protocol	\$5,500
COPD Regenerative Program	3-dose clinical protocol	\$15,000

Systemic Regenerative Therapy

Systemic SMS cell therapy administered intravenously using patient-specific dosing parameters.

Program	Dosing Basis	Program Price
Systemic IV Therapy	Patient-specific dosing	\$7,500

Clinical Considerations

SMS cell dosing is determined by indication, treatment approach, and clinical objectives

Customized treatment programs may be available upon request

SMSbiotech investigational therapies are provided within structured clinical programs and are not positioned as commodity biological products

Program Information

All pricing quoted in USD

Clinical supply prepared and distributed from California, USA

Pricing valid as of January 1, 2026
Expires on June 1, 2026

Pricing reviewed periodically to reflect clinical and operational updates

Clinic Program Requests

For clinic program requests & status inquiries:
orders@smsbiotech.com
 (Please reference applicable program or partner code, if available)

For non-standard or customized program requests:
p.cooke@smsbiotech.com

Confidential & Proprietary

This document contains confidential information of SMSbiotech and is intended solely for authorized recipients. It may not be shared or distributed without prior written consent. This document is intended for informational and clinical planning purposes only.

2026.0217.1

Onboarding

Our onboarding framework is designed to ensure full scientific, regulatory, and operational alignment from day one. Each step builds toward a seamless and supported first patient treatment.

1. Commercial & Strategic Alignment
2. Legal & Compliance
3. Site Visits & Readiness
4. Clinical Training & Product Familiarization
5. Logistics & Supply Chain
6. Resource & Documentation Access
7. Data Collection & Outcomes
8. Administrative & Financial Setup
9. Go-Live / Kickoff



Small Mobile Stem Cell (SMS) Continuous Unlimited Production

2018

GMP facility Quality Controls Checks
Sterility • Stability • Potency

SMS cells products **scale out.**

Today



SINGLE DONOR

MULTIPLE HARVESTS

TRILLIONS OF SMS CELLS

LIVE. FRESH. READY.

2018 | Single Donor Isolation

Continuously expanding, donor-independent source.

- Two blood vials. One donor.
- Stable SMS cell line established.

Continuous GMP Production

Multiple harvests enable sustained scale-out.

- Allogeneic — Donor Independent
- Off-the-Shelf & Scalable
- Proprietary & Economical

Production Today

Repeatable. Controlled. Reliable.

- Trillions of SMS cells produced
- 52 GMP batches of Prime EC
- Continuous scale-out capability
- Validated 4°C storage & shipment

Live Clinical Delivery

Clinics order live SMS cells prepared per patient — not cryopreserved inventory.

- Shipped at 4°C
- No thawing required
- No freeze-thaw viability loss
- Ready for administration upon receipt

Intellectual Property: Patents

Scientific Community & Intellectual Property Experts have validated SMS are a discrete cell type with novel proprietary knowledge on isolation and amplification

In cooperation with a leading IP firm, Knobbe Martens, SMSbiotech has filed 15 patents and has received 7.

We obtained our first patent in 2018.



 SMSbiotech

[Small Mobile Stem Cells \(Sms\) And Uses Thereof](#)

(US20190010448A1)

 SMSbiotech

[Compositions And Methods For Using Small Mobile Stem Cells](#)

(US20200299649A1)

 SMSbiotech

[Compositions And Methods For Using Small Mobile Stem Cells](#)

(UK)

 SMSbiotech

[小型運動性幹細胞を使用した組成物および方法](#)

(Japan JP2019513416A)

 SMSbiotech

[Extracellular Matrix Protein Compositions And Methods For Treating Wounds](#)

(WO2020068432A1)

細胞外マトリックスタンパク質組成物および創傷の治療方法

(Japan)

 SMSbiotech

[Method and kit for vessel formation using SMS stem cell-produced ECM and substrates](#)

(WO2021071697A1)

 SMSbiotech

[Stem Cell Compositions And Methods Of Repairing Tissue](#)

(WO2021183287)

In addition to patents, SMSbiotech owns TRADE SECRETS involving the biomanufacturing of the SMS cells and its quality control

Clinical Partnership Pathway



Confirm clinic interest in integrating SMS cells



Conduct scientific and clinical platform presentation



Align on regulatory pathway and cell supply framework

Supported by formal MOU, regulatory review, and clinical training protocols.

Typical Timeline: 4–12 Weeks Depending on Jurisdiction



Thank You & Questions?



On a mission to democratize the application of
stem cell technologies for human health

Headquarters:
1825 Diamond Street, Ste 101
San Marcos, CA 92078

www.smsbiotech.com

Inquiries

Paul Cooke

Vice President Sales
+ 1 411 746 897
p.cooke@smsbiotech.com

Faris Awad

Business Development Manager
760-290-3406
f.awad@smsbiotech.com
